This story was updated at 5:20 p.m. on Wednesday, Oct. 6, 2021.
WASHINGTON — The White House announced Wednesday that it will buy $1 billion worth of rapid, at-home coronavirus tests to address ongoing shortages, a plan hailed by public health experts who called the move long overdue.
The actions will quadruple the number of tests available to Americans by December, according to Jeff Zients, the White House coronavirus response coordinator. The news follows Monday’s decision by the Food and Drug Administration to allow the sale of an antigen test from U.S.-based Acon Laboratories.
The White House expects that that decision and the purchase of the additional tests will increase the number of at-home tests to 200 million per month by December.
“This is a big deal” said Scott Becker, chief executive officer of the Association of Public Health Laboratories, who said the spotty availability of rapid tests had hampered efforts to track and combat the surge of coronavirus cases driven by the hyper-transmissable delta variant. “The White House is beginning to take testing as seriously as they’ve taken vaccinations.”
The administration is also aiming to increase free testing by doubling President Joe Biden’s earlier commitment to expand the number of pharmacies in the federal government’s free testing program to 20,000, Mr. Zients said at a news briefing Wednesday. Mr. Biden last month announced a coronavirus response plan that envisioned a significant expansion of testing capacity.
The U.S. has lagged behind several European and Asian countries in testing for much of the pandemic, with many Americans reporting in recent months that they have struggled to get testing appointments or to be able to purchase at-home tests. Public health experts faulted the FDA for not moving faster to expedite the tests’ availability.
“These tests are cheap to make — and there’s a lot of demand for it out there,” said Dr. Ashish Jha, dean of the Brown University School of Public Health. “The reason the market hasn’t worked is because the FDA has made it very difficult for these tests to get out into the marketplace.”
The FDA declined to comment. But officials have said in the past they are concerned that some of the rapid antigen tests, which deliver results within minutes, are less accurate than the slower PCR tests that need to be evaluated in a laboratory. Australian company Ellume this month recalled roughly 195,000 of its at-home coronavirus antigen tests after discovering an increased chance that the affected kits would return false positive results.
Mr. Zients said the testing companies Quidel and OraSure are also rapidly expanding the production of their at-home tests to get more on the market. When pressed on why the White House did not increase the availability of such tests sooner, Mr. Zients said the tests only became available earlier this year.
By the end of the year, Mr. Zients said, the U.S. should have about half a billion tests available per month between at-home tests and PCR tests that people can take at a local pharmacy, clinic or doctors office. “Together, the steps we’re taking will ensure that every American, no matter their income level or Zip code, can access accurate, convenient and affordable testing,” he said.
Advocates of rapid tests say the tests perform a vital function in curbing the spread of the virus and more of them should have been authorized by now.
“This slow trickle of [emergency authorizations] is all but promising to get us a large supply of rapid tests just in time for them to no longer be as effective against delta,” added Dr. Michael Mina, a Harvard University epidemiologist who has advocated for at-home testing. “There are amazing tests produced in the billions that simply don’t exist here in the U.S.”
One potential complication of the expansion of at-home testing is the impact on official counts of positive cases. Some of the at-home tests have an app that help people report positive cases so they get added to the official government tally, but the administration will also rely on people to self-report when an at-home test shows they are infected, said CDC director Dr. Rochelle Walensky.
Some experts said it will be critical for the government to educate people about when the tests should be used and how they should report positive results.
“It’s a relief to have access to rapid testing but it will be critical to understand how to broadly disseminate and give guidance about when best to use these tests,” said Dr. Kavita Patel, a primary care physician and nonresident fellow at the Brookings Institution who served in the Obama administration. “The last thing we want is for tests to go unused and sit on shelves but you also need to give guidance to understand when these tests should be used.”
Mr. Becker also called on the Biden administration to pursue a public education campaign on the value of at-home testing so Americans would know “when to use it, how to use it, and what do you do with the results.”
Experts had clamored for the government to invest in widespread availability of rapid tests, saying that improved detection of coronavirus outbreaks could have tamped down the virus’ spread, particularly in the early months of the pandemic.
“We wasted much of last year when it would’ve really made a huge difference, before we had vaccines,” said Dr. Jha.
Mr. Becker cautioned that the rise of at-home testing could hamper public tracking of coronavirus cases, since at-home test results often do not get reported to public health officials. “It’s really on the honor system,” he said.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.